There are numerous instruments used to measure stigma in people with MS, creating ambiguity about different stigma types and their definitions and complicating the ability to generalize study findings.
Qualitative findings highlight gaps in patient education, access to evidence-based interventions, and understanding of the experiences of people with multiple sclerosis and bladder and bowel dysfunction across cultures and health care systems.
More data are needed to ascertain the actual risks and benefits of DMT use, discontinuation, and de-escalation in older people with MS.